Idex: Q3 Earnings Snapshot

IDEX Corp. (IEX) reported Q3 net income of $144.1M, or $1.95 per share, exceeding analyst estimates. Adjusted EPS was $2.33. Revenue was $951.7M, also beating forecasts. The company raised its full-year EPS guidance to $8.91-$8.96 per share.

Original reporting
Published Oct 28, 2026, 6:37 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 28, 2026, 6:59 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Idex: Q3 Earnings Snapshot — source image
Decision brief

The 30-second read

$IEXBullishMed
01

Why it matters

The earnings beat and raised guidance may trigger short‑term buying interest and support the stock price.

02

Market read

First‑report earnings with a beat and solid guidance provide a clear trading catalyst for IEX.

03

What to watch

Potential supply‑chain constraints or upcoming capital expenditures are not addressed in the release.

Relevance 8/10Novelty 8/10Timing: after-hours release

Background

Idex Corp (IEX) is a manufacturer of rescue and industrial equipment, known for the Jaws‑of‑Life device.

Company-level read

Ticker impact

$IEXBullishHigh confidence
Context

Idex Corp reported Q3 net income of $144.1M, EPS $1.95, beating estimates and gave FY guidance of $8.91‑$8.96 per share.

Expected impact

upward pressure as market prices in the earnings beat and higher guidance

Evidence & confidence

The company exceeded Wall Street expectations on both earnings and revenue, and provided a solid full‑year outlook.

Market effects

Industrial equipment sector may see modest uplift as Idex's beat suggests demand strength.

U.S. industrial stocks could benefit from the positive earnings surprise.

Limited to U.S. markets; no broader macro impact.

Counterpoint

If guidance falls short of analyst expectations, the stock could face disappointment despite the beat.

Key entities

  • Idex Corp

    Industrial equipment manufacturer reporting Q3 results.

Related articles

$IEXHighAI 8/10

DA Davidson raises IDEX stock price target to $245 on strength

DA Davidson raised its price target on IDEX Corp (NYSE:IEX) to $245 from $240, citing strength in its Health & Science Technologies and Fire & Safety segments. The stock has risen 39% over the past year. IDEX reported Q3 2026 earnings of $2.33 per share, beating estimates, with revenue of $952 million. The company also raised its full-year guidance.

$IEXHighAI 8/10

IDEX (IEX) Q3 2026 Earnings Call Transcript

IDEX (IEX) reported Q3 2026 net sales of $952M, up 8%, and adjusted EPS of $2.33, up 15%. Organic orders reached $991M, growing 13%. HST, FMT, and FSDP segments showed growth. Full-year guidance raised: organic growth 6.5-6.8%, adjusted EPS $8.91-$8.96. Inflation and chemical sector weakness noted as risks.

$IEXHighAI 8/10

IDEX Q3 2026 slides: advantaged markets drive beat, guidance raised

IDEX Corporation (NYSE:IEX) reported Q3 2026 earnings with 8% organic sales growth and 15% increase in adjusted EPS, driven by 'advantaged markets'. Sales reached $952M, adjusted EBITDA margin expanded to 27.8%, and free cash flow grew 14%. The company raised its full-year outlook, with shares up 0.92% to $235.35. HST segment led growth with 13% organic sales growth.

$IEXMedAI 8/10

IDEX (NYSE:IEX) beats Q3 2026 sales expectations

IDEX reported Q3 2026 revenue of $951.7 million, beating estimates by 1.8%. Adjusted EPS was $2.33, a 4% beat. Adjusted EBITDA reached $264.8 million, a 3.2% beat. Management raised full-year adjusted EPS guidance to $8.94. Operating margin remained steady at 21.9%, while free cash flow margin improved to 22.5%.

$IEXHighAI 9/10

IDEX beats estimates and lifts guidance as orders surge

IDEX Corporation (NYSE:IEX) reported Q3 earnings of $2.33 per share, beating estimates by $0.09, with revenue of $952M, up 8% YoY. Orders rose 13% to $991M. The company raised full-year EPS guidance to $8.91-$8.96 and increased organic sales growth outlook to 6.5%-6.8%. Shares rose 2.4% post-announcement. Growth was driven by AI and semiconductor demand, particularly in the Health & Science Technologies segment.